Wed, October 20, 2010
Tue, October 19, 2010
Mon, October 18, 2010
Sun, October 17, 2010
Sat, October 16, 2010
Fri, October 15, 2010
[ Fri, Oct 15th 2010 ]: Market Wire
ALGN, FCN, GOOG, SWY, GCI
Thu, October 14, 2010
Wed, October 13, 2010
Tue, October 12, 2010
Mon, October 11, 2010
[ Mon, Oct 11th 2010 ]: Market Wire
SNY,GENZ,LH,AVB,MU
[ Mon, Oct 11th 2010 ]: Market Wire
ARAY,SI,VAR,TOMO,JMBA
Sun, October 10, 2010
Sat, October 9, 2010
Fri, October 8, 2010
Thu, October 7, 2010
[ Thu, Oct 07th 2010 ]: Market Wire
30pm CST
Wed, October 6, 2010
Tue, October 5, 2010
Mon, October 4, 2010
Sun, October 3, 2010
Fri, October 1, 2010
Thu, September 30, 2010
Wed, September 29, 2010
Tue, September 28, 2010

ARYx Therapeutics Receives NASDAQ Notice of Non-Compliance

  Copy link into your clipboard //health-fitness.news-articles.net/content/2010/ .. cs-receives-nasdaq-notice-of-non-compliance.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

FREMONT, Calif.--([ BUSINESS WIRE ])--ARYx Therapeutics, Inc. (NASDAQ:ARYX) today announced that ARYx was notified October 5, 2010 by the staff of the NASDAQ Stock Market that it has not regained compliance with the $50 million minimum market capitalization requirement for continued listing on The NASDAQ Global Market, as set forth in Listing Rule 5450(b)(2)(A). As a result, ARYxa™s common stock is subject to delisting from the NASDAQ Global Market unless the Company requests a hearing before a NASDAQ Listing Qualifications Panel (aPanela). Accordingly, ARYx intends to timely request a hearing before a Panel, automatically staying further action by NASDAQ until the Panel issues its decision following the hearing. At the hearing, ARYx will present its plan to regain compliance. In connection with such appeal, the Panel may grant ARYx, in its sole discretion, an additional compliance period of up to 180 calendar days from the date of the NASDAQ staffa™s determination to regain compliance with the minimum market capitalization requirement for continued listing on The NASDAQ Global Market. There is no assurance that ARYxa™s planned hearing before the Panel on the delisting determination will be successful.

About ARYx Therapeutics, Inc.

ARYx Therapeutics is a biopharmaceutical company focused on developing a portfolio of internally discovered products designed to eliminate known safety issues associated with well-established, commercially successful drugs. ARYx uses its RetroMetabolic Drug Design technology to design structurally unique molecules that retain the efficacy of these original drugs but are metabolized through a potentially safer pathway to avoid specific adverse side effects associated with these compounds. ARYx currently has four products in clinical development: a prokinetic agent for the treatment of various gastrointestinal disorders, naronapride (ATI-7505); an oral anticoagulant agent for patients at risk for the formation of dangerous blood clots, tecarfarin (ATI-5923); an oral anti-arrhythmic agent for the treatment of atrial fibrillation, budiodarone (ATI-2042); and, an agent for the treatment of schizophrenia and other psychiatric disorders, ATI-9242. Please visit ARYxa™s Website at [ www.aryx.com ] for additional information.